Prometheus Laboratories Inc. Launches the First Serogenetic Test to Predict Risk of Complications From Crohn's Disease
The PROMETHEUS® Crohn's Prognostic test combines six serologic markers and three genetic mutation markers to provide physicians with a personalized serogenetic profile for their patients. This will help enable physicians to quantify these patients' risk of developing disease complications and is designed to provide information to assist physicians in determining optimal treatment strategies for their Crohn's patients.
"The Prometheus Crohn's Prognostic allows clinicians to use serologic and genetic information in order to stratify patients relative to their risk of disease progression," said Marla Dubinsky, M.D., Director of the IBD Pediatric Center at Cedars Sinai Medical center in Los Angeles. "This approach may help physicians develop a more individualized treatment plan for each patient and help them explain the risk/benefit ratio of these treatments to their patients and their families."
About Crohn's Disease
Crohn's disease is a chronic disorder that causes inflammation of the digestive or gastrointestinal tract. Symptoms of the disease include diarrhea, abdominal pain, fever and rectal bleeding. Crohn's patients may require long-term medical care, including multiple hospitalizations, surgeries and therapeutics. The condition can be difficult to manage clinically and consumes a substantial amount of healthcare resources in terms of physician time, procedures and medications. Crohn's disease is estimated to affect between 400,000 and 600,000 individuals in North America.
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with a comprehensive solution to treat chronic diseases. Prometheus' corporate offices are located in San Diego, California.
SOURCE Prometheus Laboratories Inc.